Patents by Inventor David P. M. Pleynet

David P. M. Pleynet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds that modulate intracellular calcium
    Patent number: 8524765
    Abstract: Described herein are compounds and pharmaceutical compositions containing compounds of Formula (I), which modulate the activity of store-operated calcium (SOC) channels: wherein R1, R2 and R4 are defined herein. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: September 3, 2013
    Assignee: Calcimedica, Inc.
    Inventors: Gonul Velicelebi, Kenneth A. Stauderman, David P. M. Pleynet, Soan Cheng, Jeffrey P. Whitten
  • COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM
    Publication number: 20120289587
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.
    Type: Application
    Filed: July 19, 2012
    Publication date: November 15, 2012
    Applicant: CalciMedica, Inc.
    Inventors: Gonul Velicelebi, Kenneth A. Stauderman, David P.M. Pleynet, Soan Cheng, Jeffrey P. Whitten
  • Compounds that modulate intracellular calcium
    Patent number: 8263641
    Abstract: Described herein are compounds of Formula I and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also describe herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: September 11, 2012
    Assignee: Calcimedica, Inc.
    Inventors: Gonul Velicelebi, Kenneth A. Stauderman, David P. M. Pleynet, Soan Cheng, Jeffrey P. Whitten
  • COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM
    Publication number: 20090137659
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.
    Type: Application
    Filed: August 15, 2008
    Publication date: May 28, 2009
    Applicant: CALCIMEDICA, INC.
    Inventors: Gonul VELICELEBI, Kenneth A. STAUDERMAN, David P.M. PLEYNET, Song CHENG, Jeffrey P. WHITTEN
  • Substituted heterocycles for the treatment of diabetes and other diseases
    Patent number: 7226940
    Abstract: The present invention relates to certain substituted heterocycles of Formula (I) which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, adipocyte differentiation, uncontrolled proliferation, such as lymphoma, Hodgkin's Disease, leukemia, breast cancer, prostate cancer or cancers in general; and inflammation, such as osteoarthritis, rheumatoid arthritis, Crohn's Disease or Inflammatory Bowel Disease
    Type: Grant
    Filed: August 24, 2005
    Date of Patent: June 5, 2007
    Assignees: Incyte San Diego, Inc., Ortho McNeil Pharmaceutical Inc.
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien A. Al-Shamma, Andrea Fanjul, David P. M. Pleynet, Lyle W. Spruce
  • Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
    Patent number: 7153875
    Abstract: The invention relates to certain heterocyclic compounds useful for the treatment of cancer and other diseases, having the Formula (I): wherein: (a) m is an integer 0 or 1; (b) R12 is an alkyl, a substituted alkyl, a cycloalkyl, a substituted cycloalkyl, a heterocyclic, a substituted heterocyclic, a heteroaryl, a substituted heteroaryl, an aryl or a substituted aryl residue; (c) Ar3 is an aryl, a substituted aryl, a heteroaryl or a substituted heteroaryl residue; (d) Ar4 is an aryl, a substituted aryl, a heteroaryl or a substituted heteroaryl residue; (e) R5 is hydrogen, hydroxy, alkyl or substituted alkyl; (f) ----- represents a bond present or absent; and (g) W, X, Y and Z are independently or together —C(O)—, C(S), S, O, or NH; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 7, 2002
    Date of Patent: December 26, 2006
    Assignee: Incyte San Diego
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien A. Al-Shamma, Andrea Fanjul, David P.M. Pleynet, Lyle W. Spruce, Torsten R. Wiemann, Jason B. Ibarra
  • N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases
    Patent number: 7071218
    Abstract: The present invention relates to certain compounds of Formula (I) which can be useful in the treatment of diseases, such as, cancer, metabolic disorders, Type 2 Diabetes, dyslipidemia and/or hyperchloesterolemia:
    Type: Grant
    Filed: November 15, 2002
    Date of Patent: July 4, 2006
    Assignees: Incyte San Diego Incorporated, Ortho McNeil Pharmaceutical Inc.
    Inventors: Magnus Pfahl, Catherine Tachdjian, Lyle W. Spruce, Hussien A. Al-Shamma, Mohamed Boudjelal, Andrea N. Fanjul, Torsten R. Wiemann, David P. M. Pleynet
  • Imidazolidinedione derivatives for the treatment of diabetes and other diseases
    Patent number: 6974826
    Abstract: The present invention relates to certain substituted heterocycles of Formula (I) which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, adipocyte differentiation, uncontrolled proliferation, such as lymphoma, Hodgkin's Disease, leukemia, breast cancer, prostate cancer or cancers in general; and inflammation, such as osteoarthritis, rheumatoid arthritis, Crohn's Disease or Inflammatory Bowel Disease.
    Type: Grant
    Filed: July 19, 2004
    Date of Patent: December 13, 2005
    Assignees: Incyte San Diego Inc., Ortho McNeil Pharmaceutical Inc.
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien A. Al-Shamma, Andrea Fanjul, David P. M. Pleynet, Lyle W. Spruce
  • Thiazolidinedione derivatives for the treatment of diabetes and other diseases
    Patent number: 6765013
    Abstract: The present invention relates to certain substituted heterocycles of Formula (I) which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, adipocyte differentiation, uncontrolled proliferation, such as lymphoma, Hodgkin's Disease, leukemia, breast cancer, prostate cancer or cancers in general; and inflammation, such as osteoarthritis, rheumatoid arthritis, Crohn's Disease or Inflammatory Bowel Disease.
    Type: Grant
    Filed: December 31, 2002
    Date of Patent: July 20, 2004
    Assignee: Incyte San Diego
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien A. Al-Shamma, Andrea Fanjul, David P. M. Pleynet, Lyle W. Spruce
  • 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
    Publication number: 20040097566
    Abstract: The present invention relates to certain substituted heterocycles, including 2-substituted thiazolidinone and 2-substituted oxazolidinone compounds. These compounds are useful in the treatment of diseases related to uncontrolled cellular proliferation, such as cancer or precancerous conditions. The compounds are also useful for modulating lipid and/or carbohydrate metabolism, and treating Type II diabetes, hyperglycemia or obesity, and for treating inflammatory diseases such as arthritis.
    Type: Application
    Filed: December 6, 2002
    Publication date: May 20, 2004
    Inventors: Magnus Pfahl, Hussien A. Al-Shamma, Andrea Fanjul Giachino, David P. M. Pleynet, Haifeng Bao, Lyle W. Spruce, Christopher N. Cow, Catherine Tachdjian, James W. Zapf, Torsten R. Wiemann
  • Thiazolidinedione derivatives for the treatment of diabetes and other diseases
    Publication number: 20030153606
    Abstract: The present invention relates to certain substituted heterocycles of Formula (I) which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, adipocyte differentiation, uncontrolled proliferation, such as lymphoma, Hodgkin's Disease, leukemia, breast cancer, prostate cancer or cancers in general; and inflammation, such as osteoarthritis, rheumatoid arthritis, Crohn's Disease or Inflammatory Bowel Disease.
    Type: Application
    Filed: December 31, 2002
    Publication date: August 14, 2003
    Applicant: Maxia Pharmaceuticals, Inc.
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien A. Al-Shamma, Andrea Fanjul, David P.M. Pleynet, Lyle W. Spruce
  • N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases
    Publication number: 20030144329
    Abstract: The present invention relates to certain compounds of Formula (I) which can be useful in the treatment of diseases, such as, cancer, metabolic disorders, Type 2 Diabetes, dyslipidemia and/or hyperchloesterolemia: 1
    Type: Application
    Filed: November 15, 2002
    Publication date: July 31, 2003
    Inventors: Magnus Pfahl, Catherine Tachdjian, Lyle W. Spruce, Hussien A. Al-Shamma, Mohamed Boudjelal, Andrea N. Fanjul, Torsten R. Wiemann, David P.M. Pleynet
  • RXR activating molecules
    Publication number: 20030105333
    Abstract: Disclosed are molecules that activate an RXR receptor, wherein the molecule comprises an RXR binding portion which binds the RXR receptor and comprises a side pocket contacting residue which contacts a side-pocket 1 of an RXR receptor.
    Type: Application
    Filed: March 8, 2002
    Publication date: June 5, 2003
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien A. Al-Shamma, Andrea N. Fanjul, David P.M. Pleynet, Lyle W. Spruce, Richard Fine, James W. Zapf, Jianhua Guo, Karine Jakubowicz-Jaillardon
  • Heterocyclic derivatives for the treatment of diabetes and other diseases
    Patent number: 6515003
    Abstract: The present invention relates to certain substituted heterocycles of Formula (I) which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, adipocyte differentiation, uncontrolled proliferation, such as lymphoma, Hodgkin's Disease, leukemia, breast cancer, prostate cancer or cancers in general; and inflammation, such as osteoarthritis, rheumatoid arthritis, Crohn's Disease or Inflammatory Bowel Disease.
    Type: Grant
    Filed: August 31, 2000
    Date of Patent: February 4, 2003
    Assignee: Maxia Pharmaceuticals, Inc.
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien A. Al-Shamma, Andrea Fanjul, David P. M. Pleynet, Lyle W. Spruce
  • Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
    Publication number: 20020143182
    Abstract: The invention relates to certain heterocyclic compounds useful for the treatment of cancer and other diseases, having the Formula (I): 1
    Type: Application
    Filed: March 7, 2002
    Publication date: October 3, 2002
    Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien A. Al-Shamma, Andrea Fanjul, David P.M. Pleynet, Lyle W. Spruce, Torsten R. Wiemann, Jason B. Ibarra